The Netherlands Cancer Institute
Amsterdam 1066CX
2 studies enrolling now · 15 studies all time
What they study most
Aggressive Fibromatosis, Carcinoma, Non-Small-Cell Lung, Childhood Teratoma, Choriocarcinoma, Desmoid, Desmoid Tumor, Endometrial Cancer, Esophageal Squamous Cell Carcinoma, Extragonadal Seminoma, Gastric Cancer, Gastrointestinal Stromal Tumors, Germ Cell Tumor
Studies at this site
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors — Recruiting now
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — Recruiting now
- A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors — Running, not enrolling
- A Study of AL102 in Patients With Progressing Desmoid Tumors — Running, not enrolling
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors — Running, not enrolling
- Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma — Running, not enrolling
- Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma — Running, not enrolling
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib — Running, not enrolling
- PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors — Stopped early
- IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) — Running, not enrolling
- Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) — Completed
- Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer — Completed
- Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations — Stopped early
- Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 — Completed